Your browser doesn't support javascript.
loading
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono, Johann S; Concin, Nicole; Hong, David S; Thistlethwaite, Fiona C; Machiels, Jean-Pascal; Arkenau, Hendrik-Tobias; Plummer, Ruth; Jones, Robert Hugh; Nielsen, Dorte; Windfeld, Kristian; Ghatta, Srinivas; Slomovitz, Brian M; Spicer, James F; Yachnin, Jeffrey; Ang, Joo Ern; Mau-Sørensen, Paul Morten; Forster, Martin David; Collins, Dearbhaile; Dean, Emma; Rangwala, Reshma A; Lassen, Ulrik.
Afiliação
  • de Bono JS; The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@irc.ac.uk.
  • Concin N; BGOG and Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Hong DS; Phase I Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thistlethwaite FC; Department of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Machiels JP; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium.
  • Arkenau HT; Sarah Cannon Research Institute, University College of London, London, UK.
  • Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle University, Newcastle, UK.
  • Jones RH; Velindre Cancer Centre and Cardiff University, Cardiff, UK.
  • Nielsen D; Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Cophenhagen, Denmark.
  • Windfeld K; Genmab, Copenhagen, Denmark.
  • Ghatta S; Genmab US, Princeton, NJ, USA.
  • Slomovitz BM; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
  • Spicer JF; Guy's Hospital, King's College London, London, UK.
  • Yachnin J; Karolinska University Hospital, Solna, Sweden.
  • Ang JE; The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK.
  • Mau-Sørensen PM; Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
  • Forster MD; UCL Cancer Institute, University College London Hospitals, London, UK.
  • Collins D; Department of Medical Oncology, Cork University Hospital, Cork, Ireland.
  • Dean E; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium.
  • Rangwala RA; Genmab US, Princeton, NJ, USA.
  • Lassen U; Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
Lancet Oncol ; 20(3): 383-393, 2019 03.
Article em En | MEDLINE | ID: mdl-30745090
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Imunoconjugados / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Imunoconjugados / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article